Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $222 to $210.
June 20, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Jazz Pharmaceuticals but lowers the price target from $222 to $210.
The maintained Buy rating suggests continued confidence in Jazz Pharmaceuticals' prospects, but the lowered price target indicates some caution regarding its short-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100